Emtricitabine/rilpivirine/tenofovir

Emtricitabine/rilpivirine/tenofovir, a wɔtɔn wɔ din Complera mu no yɛ nnuru a wɔde di HIV/AIDS ho dwuma. Gilead Sciences ne Johnson & Johnson's Tibotec na wɔyɛɛ aduru no, na US Food and Drug Administration (FDA) penee so wɔ August 2011, na European Medicines Agency nso penee so wɔ November 2011, maa ayarefo a wonnyaa HIV ho ayaresa da. Wonya no te sɛ kuruwa biako a wotwa no da biara.

Nnuruyɛ dwumadie

sesa

Wɔde emtricitabine/rilpivirine/tenofovir di dwuma de sa HIV- 1 yareɛ wɔ mpanimfoɔ a wonnii HIV- 1 nnuru da (berɛ a yareɛ mmoawa no antumi annye nnuro a ɛko tia HIV- 1 yi ano) na wonni HIV- 1 RNA a ɛboro 100,000 wɔ mL biara mu wɔ wɔn mogya mu ( "viral load")[1][2]

Baabi a menyaa mmoa firiiɛ

sesa
  1. Kiran A. Faryar, Rachel M. Ancona, Zachary Reau, Sheryl B. Lyss, Robert S. Braun, Todd Rademaker, Ryane K. Sickles, Michael S. Lyons (2021-05-18), "HIV detection by an emergency department HIV screening program during a regional outbreak among people who inject drugs", PLOS ONE, vol. 16, no. 5, pp. e0251756, doi:10.1371/journal.pone.0251756, ISSN 1932-6203, retrieved 2024-08-24{{citation}}: CS1 maint: multiple names: authors list (link)
  2. Tom A. Reilly (1986-09-22), A review of vein mineralization in SW County Cork, Ireland., Irish Association for Economic Geology, doi:10.61153/vwah1117, retrieved 2024-08-24 {{citation}}: Check |doi= value (help)